Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Nov

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Focus on Optimized Dosing of Ibrutinib Panel Discussion

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer

AI Simplifies Patients Comprehension of CT Reports But Are Errors Possible

ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer

FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer